規制動向
FDA、EMA、TGA および世界の規制動向
規制動向
2026年9月8日•1分で読めます
FDA Approves Labeling Updates for Chartwell Rx’s Discontinued Desloratadine Tablet (ANDA078364)
The FDA has granted several labeling approvals for Chartwell Rx’s desloratadine 5 mg oral tablet (ANDA078364), though the product is listed as discontinued.
規制動向
2026年9月8日•1分で読めます
FDA Approves CALCITRIOL Injection (ANDA078066)
FDA granted approval for CALCITRIOL injectable products (ANDA078066) from LONG GROVE PHARMS, including a prescription 0.001 mg/mL product and a discontinued 0.002 mg/mL version.
規制動向
2026年9月8日•1分で読めます
FDA Approves ANDA077766 for Simvastatin Generic Tablets
The FDA granted approval for Chartwell Rx's ANDA077766, covering five discontinued Simvastatin tablet strengths and subsequent labeling updates.
規制動向
2026年9月8日•1分で読めます
FDA Approves Labeling for Teva’s Discontinued Ramipril Capsules (ANDA 077470)
Teva Pharmaceuticals’ oral ramipril capsule products (1.25‑10 mg) were listed as discontinued, with multiple FDA labeling supplements approved between 2008 and 2014.
規制動向
2026年9月8日•1分で読めます
FDA Approves ANDA076589 for FLUMAZENIL Injectable Products
FDA approved ANDA076589 submitted by Dr Reddys, covering two injectable FLUMAZENIL products, both listed with discontinued marketing status.
規制動向
2026年9月8日•1分で読めます
FDA Approves ANDA077165 for Granisetron Hydrochloride Preservative‑Free Injection (DR REDDYS)
The FDA approved ANDA077165 for a preservative‑free granisetron hydrochloride injectable product by Dr. Reddys; the product is listed as discontinued.
規制動向
2026年9月8日•1分で読めます
Samjin and Jongkundang Voluntarily Cut Prices of Epilepsy and Ezetimibe Drugs
Samjin’s third‑generation epilepsy drug Brivaracetam and Jongkundang’s ezetimibe combo LypiroUjet will have reduced insurance prices from next month, with cuts ranging 3‑11%.
規制動向
2026年9月8日•1分で読めます
KPA Forms Emergency Committee to Counter Expanded Telemedicine Prescription Delivery Policy
The Korean Pharmaceutical Association establishes an emergency response committee to address the government’s plan to broaden delivery of prescription drugs for telemedicine patients.
規制動向
2026年9月8日•1分で読めます
PMDA Requests Public Comments on Draft Regulatory Science Standards
The Japan PMDA invites comments on draft standards, noting email address formatting and confidentiality rules.
規制動向
2026年9月8日•1分で読めます
PMDA Invites Public Comments on Draft Regulatory Science Standards
The PMDA outlines how to submit comments on draft regulatory science standards, noting email formatting, public disclosure of submissions, and no individual replies.
規制動向
2026年9月8日•1分で読めます
FDA Approves Sandoz ANDA076873 for Metformin Hydrochloride Extended‑Release Tablet
The FDA has approved Sandoz's ANDA076873 for a prescription oral metformin hydrochloride 500 mg extended‑release tablet, with multiple labeling supplements approved.
規制動向
2026年9月8日•1分で読めます
FDA Approves ANDA083022 for DODEX Injectable (Cyanocobalamin)
The FDA approved ANDA083022 for the DODEX injectable containing 1 mg/mL cyanocobalamin. The product is listed as discontinued.